Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.

× No keyword cloud information.

18 in total

1. Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R²) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma.

Authors: Koji Izutsu; Yosuke Minami; Noriko Fukuhara; Yasuhito Terui; Tatsuro Jo; Go Yamamoto; Takayuki Ishikawa; Tsutomu Kobayashi; Toru Kiguchi; Hirokazu Nagai; Tomoko Ohtsu; Stacey Kalambakas; Pierre Fustier; Shuichi Midorikawa; Kensei Tobinai
Journal: Int J Hematol Date: 2019-12-19 Impact factor: 2.490

2. Haematological cancer: Rituximab enhances responses to lenalidomide.

Authors: Peter Sidaway
Journal: Nat Rev Clin Oncol Date: 2016-12-13 Impact factor: 66.675

Review 3. Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy.

Authors: Sabarish Ayyappan; Basem M William
Journal: Curr Oncol Rep Date: 2018-03-23 Impact factor: 5.075

Review 4. Indolent lymphomas: pushing the pace with novel agents.

Authors: Caron A Jacobson
Journal: Hematology Am Soc Hematol Educ Program Date: 2019-12-06

Review 5. Nodular pulmonary amyloidosis: a complex disease with malignancy association.

Authors: Jacob M Core; Ali A Alsaad; Liuyan Jiang; Neal M Patel
Journal: BMJ Case Rep Date: 2017-10-15

Review 6. How do we sequence therapy for marginal zone lymphomas?

Authors: Alessandro Broccoli; Pier Luigi Zinzani
Journal: Hematology Am Soc Hematol Educ Program Date: 2020-12-04

Review 7. Management of Extranodal Marginal Zone Lymphoma: Present and Upcoming Perspectives.

Authors: Dominic Kaddu-Mulindwa; Lorenz Thurner; Konstantinos Christofyllakis; Moritz Bewarder; Igor Age Kos
Journal: Cancers (Basel) Date: 2022-06-19 Impact factor: 6.575

Review 8. The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma.

Authors: Jose Sandoval-Sus; Julio C Chavez
Journal: Ther Adv Hematol Date: 2021-05-29

9. Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma.

Authors: Joseph M Tuscano; Christina Poh; Paul Kaesberg; Guilluame Luxardi; Alexander Merleev; Alina Marusina; Ann Brunson; Aaron Rosenberg; Brian Jonas; Emanual Maverakis
Journal: Clin Cancer Res Date: 2021-06-04 Impact factor: 13.801

Review 10. Treatment of indolent lymphoma.

Authors: Seong Hyun Jeong
Journal: Blood Res Date: 2022-04-30

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.

1. Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma.